A significant decrease in viability was observed in simultaneous XPO1 + HSPA9 or RUVBL1/2 targeting (Fig. 3A, B) in comparison with normal fibroblasts (Fig. 3C) and typical chemotherapy protocols used for colon, lung or pancreatic cancers (Supplementary Fig. 3C). Here, HSPA9 is linked to familial pancreatic carcinoma.